Evaluation of the reintroducing FOLFOX or XELOX +/- BV in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy.(REACT study) - Evaluation of the reintroducing FOLFOX or XELOX +/- BV in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy.(REACT study)

Hyogo College of Medicine, Department of Surgery0 个研究点目标入组 30 人开始时间: 2011年10月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Blood transfusion, administration of hematopoietic factor (human blood products or G-CSF, etc). 2)Serious drug allergy. 3)Peripheral sensory neuropathy >= Grade 2. 4)Active synchronous malignancies. 5)Massive pleural or pericardial effusion ,or ascites. 6)Infection of clinical issue or fever suspicious of infection. 7)Brain metastasis. 8)Cardiac disease complications (congested heart failure, symptomatic coronary artery disease, uncontrollable cardiac dysrhythmia or history of myocardial infarction within 12 months, etc). 9)Lung disease of clinical issue. 10)Bleeding that requires medication or transfusion. 11)Uncontrolled diarrhea. 12)Ileus or bowel obstruction. 13)Clinically significant mental or psychological disease. 14)Insulin-treated diabetic patients. 15)Women who are pregnant or breast-feeding. 16)Other patients who are unfit for the study as determined by the attending physician.

发起方

Hyogo College of Medicine, Department of Surgery